TargeGen is “Fierce,” on Leading Edge of Biotech

San Diego, CA – June 7, 2007 – TargeGen announced today that it has been named to the annual FierceBiotech “Fierce 15” list, designating it as one of the top biotech companies of 2007. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. TargeGen was determined to be one of the “fiercest,” proven by their creativity and innovations in the industry.

An internationally recognized daily newsletter reaching more than 56,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day’s top stories, with a special focus on drug discovery and clinical trials.

“An efficient R&D approach along with technology that carries the promise of broad applicability, TargeGen has been racking up awards for good reason,” said John Carroll, Editor of FierceBiotech.

TargeGen’s current drug candidates include TG100801, a topically applied kinase inhibitor for the treatment of macular degeneration, TG101348, an oral drug for the treatment of myeloproliferative diseases and TG100-115 for the treatment of certain inflammatory diseases. All TargeGen drug candidates to date have been internally discovered and developed.

"FierceBiotech is renowned for its advanced understanding of biotechnology companies and the industry as a whole," said Peter G. Ulrich, Co-Founder, President and CEO of TargeGen. "Being selected as a member of the ‘Fierce 15’ is an honor that highlights TargeGen’s potential to make a significant impact in the biotech market.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The complete list of ‘Fierce 15’ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.

About FierceMarkets

FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include DailyTechRag, FierceBioResearcher, FierceBiotech, FierceBioResearcher, FierceCIO, FierceDeveloper, FierceFinance, FierceGameBiz, FierceHealthcare, FierceHealthIT, FierceIPTV, FierceMobileContent, FierceSarbox, FierceVoIP, FierceWiFi, FierceWireless, and IT-Wireless, and The Business VoIP Report.

About TargeGen, Inc.

TargeGen, which initiated operations in 2002, has been financed to date by top tier venture capital funds including Forward Ventures, Enterprise Partners, Chicago Growth Partners/William Blair Capital Partners, Vantage Point Venture Partners/CDP Capital Technology Ventures, BB Biotech, H&Q, Pappas and other investors.

For additional information, contact:

TargeGen, Inc.
Peter Ulrich
9380 Judicial Drive
San Diego, CA 92121
Tel 858-678-0760
Fax 858-678-0762
info@targegen.com
http://www.targegen.com

TMEDIA
Heather Cox
FierceMarkets, Inc.
202-628-8778 x13
heather@fiercemarkets.com